A Comprehensive Target Panel Allows to Extend the Genetic Spectrum of Neuroendocrine Tumors

Area of Science:

• Genetics
• Oncology
• Endocrinology

Background:

• Neuroendocrine tumors (NETs) often have a genetic basis, with expanding knowledge of implicated genes.
• Targeted gene panels (TGPs) using next-generation sequencing are crucial for identifying novel NET development variants.

Purpose of the Study:

• To investigate the genetic landscape of various neuroendocrine tumors (NETs) using comprehensive molecular genetic analyses.
• To identify novel germline variants associated with different NET subtypes and endocrine syndromes.

Main Methods:

• Conducted TGP analysis on 93 patients with NET subtypes: insulinoma, pheochromocytoma and paraganglioma (PPGL), parathyroid adenoma, and other NETs.
• Classified genetic variants according to American College of Medical Genetics and Genomics guidelines.

Main Results:

• Identified 30 variants in known NET-associated genes and 13 variants in genes not previously linked to the observed NETs.
• Discovered novel gene associations for insulinoma (ABCC8, KCNJ11, KLF11, HABP2, APC), PPGL (ZNRF3, GNAS, KCNJ5), parathyroid adenomas (SDHB, TP53), and other NETs (APC, ABCC8).

Conclusions:

• Broad TGP analysis effectively identifies new germline variants in functioning NETs.
• Further research with larger cohorts is needed to validate these findings and understand their clinical implications.